Dataset Information

CUA 2022 Annual Meeting Abstracts - Poster Session 6: Oncology - Penis/Testis/Urethra, Prostate Saturday, June 25, 2022 • 16:00-17:30.

ABSTRACT:

SUBMITTER:

PROVIDER: S-EPMC9239722 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

CUA 2022 Annual Meeting Abstracts - Poster Session 6: Oncology - Penis/Testis/Urethra, Prostate Saturday, June 25, 2022 • 16:00-17:30.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20220601 6 Suppl 1

PMID: 35667361

Similar Datasets

Project description:Introduction and Objectives: Optimizing targeted therapy in patients with metastatic renal cell carcinoma (RCC) would improve clinical outcomes but patient derived xenograft (PDX) models are lacking. We present a novel pre-clinical model that is superior to nude mice for accommodating RCC PDXs. This preclinical model implants RC PDXs into the chorioallantoic membrane (CAM) of avian embryos and is a patient-specific platform that could be advantageous for physicians in the future when deciding what treatment options are best for their patients. This drug panelling platform is rapid, cost-effective, and relies on the highly angiogenic CAM to support RCC PDXs. Methods: Commercial and patient derived RCC cell lines, were grown to full confluence and transduced to generate fluorescently labeled versions of each cell line. Cells were implanted into the CAM. Tumors were treated every two days by applying 10 μL (10 μM) of indicated drug onto the tumor onplant. The drugs that were paneled include Sunitinib, Sorafenib, Pazopanib, Axitinib and a vehicle treatment. After 7–8 days of incubation post-implantation, tumor take rate was determined by the presence of tumor growth in the CAM using a fluorescent stereoscope. Results: The highest tumor take rates were observed in the vehicle treatments of the embryos, ranging from 50–86%. Both commercial and primary cell lines saw a reduction in tumor take rate with the application of various anti-angiogenic drugs. Specifically, XP121 tumors were resistant to Sorafenib; 786-0, XP121; XP206 were resistant to Pazopanib; T258, XP121 were resistant to Sunitinib; and lastly, T258 tumors were resistant to Axitinib (Table 1). Conclusions: RCC PDXs onplanted in the CAM of avian embryos offer a robust and cost-effective platform to predict sensitivity/resistance to targeted therapies. When evaluating several patient-derived RCC cell lines, drug paneling revealed other alternative treatment options for these PDXs. More importantly, RCC PDXs that were shown to be Sunitinib-resistant in both the patient and in mouse-based PDXs, also produced the same resistance phenotype in the CAM.

Dataset Information

CUA 2022 Annual Meeting Abstracts - Poster Session 6: Oncology - Penis/Testis/Urethra, Prostate Saturday, June 25, 2022 • 16:00-17:30.

Publications

CUA 2022 Annual Meeting Abstracts - Poster Session 6: Oncology - Penis/Testis/Urethra, Prostate Saturday, June 25, 2022 • 16:00-17:30.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets